

Supplementary Table S1: Survival data for mouse experiments

Experiment ^a	Rad. Delivery Method and Dose	Xenograft Model	Survival Variable ^b	Control Survival	Ven. Alone Survival	Rad. Alone Survival	Additive Prediction for Combination Survival ^c	Combination Survival
1 (Figure 4A)	Ext. RT 8 Gy	MCL (Rec-1)	Mn. surv. time (days)	12.5	17.1	18	22.6	35.9
			Md. surv. time (days)	13	13	17	17	27
			Cures (%)	0	0	0	0	11
2 (Figure 4B)	Ext. RT 10 Gy	GCB-DLBCL (SU-DHL-6)	Mn. surv. time (days)	25.6	29.5	37.9	41.8	59.3
			Md. surv. time (days)	22	29	38.5	45	48.5
			Cures (%)	0	0	0	0	10
3 (Results text)	Ext. RT 6 Gy	GCB-DLBCL (SU-DHL-6)	Mn. surv. time (days)	22	26	30	34	34
			Md. surv. time (days)	22	27	27	32	33
			Cures (%)	0	0	0	0	0
4 (Results text)	Ext. RT 6 Gy	ABC-DLBCL (U2932)	Mn. surv. time (days)	24	52	27	55	65
			Md. surv. time (days)	22	53	27	58	61
			Cures (%)	0	0	0	0	0
5 (Results text)	PRIT 400μCi	MCL (Rec-1)	Mn. surv. time (days)	12	17	18	22	25
			Md. surv. time (days)	12	15	18	21	25
			Cures (%)	0	0	0	0	0
5 (Figure 5A)	PRIT 800μCi	MCL (Rec-1)	Mn. surv. time (days)	12	17	26	30	71
			Md. surv. time (days)	12	15	27	30	54
			Cures (%)	0	0	0	0	25
6 (Figure 5B)	PRIT 800μCi	ABC-DLBCL (U2932)	Mn. surv. time (days)	22	55	74	107	120
			Md. surv. time (days)	21	58	65	102	120
			Cures (%)	0	0	10	10	100
6 (Figure 5B)	PRIT 1200μCi	ABC-DLBCL (U2932)	Mn. surv. time (days)	22	55	84	117	120
			Md. surv. time (days)	21	58	66	103	120
			Cures (%)	0	0	30	30	100

^aFor all experiments, n = 8-10 mice/group. ^bFor mean and median survival calculations, long-term survivors (cures) were assigned survival times of 120 days, so survival times for groups with long-term survivors are conservative minimum estimates. Median survival time was calculated as the middle survival date for the group. Cure defined as survival for >120 days with no sign of relapse. ^cAdditive predictions for combination group survival were calculated as: (survival of venetoclax group) + (survival of radiotherapy group) – (survival of control group).